Clinical trials: Dermatologic Diseases
Breast Cancer
Study on the Efficacy and Safety of "Body-Tuning, Voice-Tuning, Mind-Tuning" Three-Dimensional Integrated Art Therapy in Regulating the Physical-Mental-Social Status of Young and Middle-Aged Breast Cancer Patients After Surgery
To evaluate the improvement effect of the "Body-Tuning, Voice-Tuning, Mind-Tuning" three-dimensional integrated art therapy on insomnia and physical-mental-social status in breast cancer patients aged ≤45 years, and to explore…
- Trial name
- ArtRehab (NCT07815262)
- Testing
- ArtRehab
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Keda Yu
Breast Cancer
An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort Study
Neoadjuvant chemotherapy is an important part of the systematic treatment of breast cancer, and it is of great clinical significance to predict the efficacy of neoadjuvant chemotherapy in early stage.
- Trial name
- NCT06510127
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Onchocerciasis
Emodepside Phase II Trial for Treatment of Onchocerciasis
The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.
- Trial name
- NCT05180461
- Testing
- emodepside, ivermectin
- Where
- 3 sites in Democratic Republic of the Congo, Ghana
- Volunteers
- 578 people
- Sponsor
- Drugs for Neglected Diseases
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted…
- Conditions
- Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT04692103
- Testing
- F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Vitiligo, Healthy
The Gut and Skin Microbiome in Vitiligo Disease Progression
Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls.
- Trial name
- NCT03577327
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Malignant Melanoma
IMCgp100-401 Rollover Study
IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
- Trial name
- NCT02889861
- Testing
- IMCgp100
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Immunocore Ltd
Systemic Sclerosis
CSL Behring Sclero XIII
Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels, mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers or toes turning white then blue in the cold)…
- Trial name
- NCT02551042
- Testing
- Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College, London
Breast Cancer, Colorectal Cancer
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
- Conditions
- Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
- Trial name
- NCT04172597
- Testing
- Poziotinib Hydrochloride, Loperamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Breast Cancer
A Study of A166 in Patients With Advanced Solid Malignant Tumors
This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
- Trial name
- NCT05311397
- Testing
- A166
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Malignant Melanoma
CP-461 in the Treatment of Patients With Advanced Melanoma
The purpose of this study is to determine the efficacy of CP-461 given twice daily orally in patients with advanced or metastatic malignant melanoma and to evaluate the safety profile of CP-461 in this patient population.
- Trial name
- NCT00060710
- Testing
- CP-461
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer
The Effect of Dexmedetomidine of the Immune System
The goal of this research study is to learn about how dexmedetomidine (a standard of care sedative) affects your immune system (your defenses against cancer) by measuring your white blood cell levels before and after surgery.
- Trial name
- NCT01692210
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
Breast cancer (BC) is the most common neoplasm in the world. In Spain, one in 8 women is diagnosed with BC. The human epidermal growth factor receptor 2 (HER2)-positive BC subtype (that represents around 20% of all BC) was…
- Trial name
- TrasTUCAN (NCT05583110)
- Testing
- Tucatinib, Trastuzumab, Vinorelbine
- Where
- 18 sites in Spain
- Volunteers
- 13 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer, Breast - Female
The Effect of Health Education Conducted Using Two Different Methods on Women's Knowledge of Breast Cancer, Health Beliefs, Mammography Self-Efficacy, and Participation in Screening Programs
Breast cancer is the most common cancer among women worldwide and can be deadly if not found early. Screening tests like mammograms help find breast cancer early, which improves the chances of successful treatment.
- Trial name
- NCT07083310
- Testing
- Health Education, Motivational Interviewing
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Skin Infection, Abscess
Complicated Skin and Skin Structure Infections
The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.
- Conditions
- Skin Infection, Abscess, Cellulitis
- Trial name
- NCT00619710
- Testing
- Meropenem, Imipenem-cilastatin
- Volunteers
- 1,000 people
- Sponsor
- Pfizer
Acne Vulgaris
De Novo Lipogenesis of Sebaceous Glands in Acne
There are two purposes of this study: 1. First, the investigators want to see what the differences are in de novo sebaceous lipid production of people with and without acne. 2.
- Trial name
- NCT02620813
- Testing
- Tretinoin, Isotretinoin
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Complicated Skin and Skin Structure Infection
Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)
This is a multi-center, investigator-blind, comparative Phase 3 study. Patients will receive either iclaprim or linezolid for 10 to 14 days.
- Trial name
- NCT00299520
- Testing
- intravenous iclaprim or intravenous linezolid
- Where
- 5 sites in United States
- Sponsor
- Arpida AG
Breast Cancer
Koning Breast Computed Tomography Guided Biopsy
The primary aim of this study is to show that the accuracy of Koning Breast CT-guided biopsy is at least equivalent to that of stereotactic-guided biopsy.
- Trial name
- NCT01750320
- Testing
- Koning Breast CT-guided Biopsy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Koning Corporation
Melanoma (Skin), Melanoma Stage IV
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1…
- Conditions
- Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
- Trial name
- TIMAR1 (NCT04904120)
- Testing
- [203Pb]VMT01, [68Ga]VMT02
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Perspective Therapeutics
Cutaneous Melanoma, Mucosal Melanoma
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
- Trial name
- ARTISTRY-6 (NCT04830124)
- Testing
- Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing
- Where
- 41 sites in United States, Australia and 6 more
- Volunteers
- 173 people
- Sponsor
- Mural Oncology, Inc
Breast Cancer, Chemotherapy-induced Alopecia
Efficacy and Safety of DIGNICAP™ System
Chemotherapy-induced alopecia (CIA) is one of the most common and emotionally distressing side effects of cancer therapy. In this study we sought to assess the feasibility and the effectiveness of scalp cooling system DigniCap®…
- Trial name
- DIGNICAP (NCT03712696)
- Testing
- DIGNICAP™
- Where
- Italy
- Volunteers
- 139 people
- Sponsor
- European Institute of Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.